Lucentis (ranibizumab) accepted for use within NHS Scotland
Lucentis (ranibizumab) has finally been accepted for use within NHS Scotland for the treatment of adults with visual impairment due to macular oedema (MO) secondary to retinal vein occlusion (RVO) (branch RVO or central RVO) following a resubmission from Novartis. The initial submission (November 2011) was not accepted by the Scottish Medicines Consortium.
